| KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169 - MarketWatch (press release) |
|
|
MarketWatch (press release) Most ESRD patients on hemodialysis are affected by CKD-MBD, which can lead to significant morbidity and mortality, including bone pain and fractures, vascular calcification and cardiovascular events. Previous Phase 2 data have demonstrated that |